Immunic, Inc. (NASDAQ:IMUX) Receives $12.67 Average PT from Analysts

Shares of Immunic, Inc. (NASDAQ:IMUX) have been assigned a consensus recommendation of “Buy” from the eight ratings firms that are covering the firm, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $12.67.

IMUX has been the topic of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Immunic in a report on Friday, February 21st. D. Boral Capital reaffirmed a “buy” rating and set a $17.00 price objective on shares of Immunic in a report on Wednesday, February 26th. Finally, StockNews.com downgraded shares of Immunic from a “hold” rating to a “sell” rating in a research note on Saturday, February 22nd.

Immunic Price Performance

NASDAQ:IMUX opened at $1.17 on Monday. The firm has a market capitalization of $105.39 million, a P/E ratio of -0.95 and a beta of 1.89. The company’s fifty day moving average price is $1.04 and its 200-day moving average price is $1.25. Immunic has a 1-year low of $0.92 and a 1-year high of $2.11.

Institutional Trading of Immunic

Several institutional investors have recently modified their holdings of IMUX. Millennium Management LLC lifted its position in shares of Immunic by 480.6% during the 4th quarter. Millennium Management LLC now owns 579,683 shares of the company’s stock worth $580,000 after buying an additional 479,846 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of Immunic by 45.6% during the 4th quarter. Renaissance Technologies LLC now owns 566,623 shares of the company’s stock worth $567,000 after buying an additional 177,542 shares during the last quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Immunic by 90.0% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 204,579 shares of the company’s stock worth $205,000 after buying an additional 96,894 shares during the last quarter. Barclays PLC purchased a new stake in shares of Immunic during the 4th quarter worth approximately $84,000. Finally, HB Wealth Management LLC purchased a new stake in shares of Immunic during the 4th quarter worth approximately $81,000. Hedge funds and other institutional investors own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.